6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
6-K - UTime Ltd (0001789299) (Filer)
SC 13D - UTime Ltd (0001789299) (Subject)
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- UTime Limited ("UTime" or the "Company") (NASDAQ:WTO), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0001 per share (the "Ordinary Shares"), at a ratio of 1-for-10, to be effective on or around the open of trading on March 31, 2025. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on or around Monday, M
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- UTime Limited ("UTime" or the "Company") (NASDAQ:WTO), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets, announced today that on October 10, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set f
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- UTime Limited ("UTime" or the "Company") (NASDAQ:WTO), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets today announced that it has entered into a securities purchase agreement with certain accredited investor to sell $5 million of its ordinary shares in a registered direct offering. Under the terms of the securities purchase agreement, UTime has agreed to sell 7,692,308 ordinary shares with a purchase price of $0.65 per share. The gross proceeds to UTime are estimated to be $5 million before deducting
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- UTime Limited ("UTime" or the "Company") (NASDAQ:WTO), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets today announced that it will effect a reverse share split of its outstanding ordinary shares, par value $0.0001 per share (the "Ordinary Shares"), at a ratio of 1-for-25, to be effective on or around the open of trading on September 11, 2024. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on or around Wednesday,
SHENZHEN, China, Aug. 29, 2024 /PRNewswire/ -- Dear Investors, Analysts and Media: Recently, UTime Ltd ("UTime") has experienced a period of unusual share price volatility in the capital markets. As a responsible company, we understand the concerns of market participants about such situations and believe that it is necessary to provide the public with transparent and formalized information in this regard. First of all, the Board of Directors and management of the Company are highly concerned about the recent unusual volatility in the share price. We are working closely with the relevant authorities to ensure that all disclosures comply with regulatory requirements and to protect the intere
SHENZHEN, China, Aug. 28, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") has officially announced the signing of a non-disclosure agreement (the "NDA") with Bowen Therapeutics Inc ("Bowen Therapeutics") for the acquisition of the Bowen Therapeutics laboratory at UMASS Medical School. This strategic move not only marks UTime's in-depth expansion in the global vaccine market, but also provides strong support for the registration of the relevant vaccine through the U.S. Food and Drug Administration (the "FDA"). One of the key drivers behind this acquisition is a growing global need for an effective monkeypox vaccine. Monkeypox, as an infectious disease caused by th
SHENZHEN, China, Aug. 26, 2024 /PRNewswire/ -- UTime Limited (NASDAQ:WTO) ("UTime" or the "Company") is excited to announce its collaboration on Circul VS, a core continuous blood pressure measurement technology system developed in partnership with strategic partner, Dr. Ehud Baron. Designed to offer patients an accurate and user-friendly continuous blood pressure monitoring solution, Circul VS facilitates early detection and long-term management, helping to reduce the risks associated with cardiovascular and cerebrovascular conditions. Circul VS features the BPwatch, Ring, and Smart Cradle, integrated into a sophisticated cloud-based network and service system. Unlike other systems on the
SHENZHEN, China, Aug. 23, 2024 /PRNewswire/ -- UTime Limited (NASDAQ:WTO) ("UTime" or the "Company") is pleased to announce its plans to participate in a series of internationally recognized medical fairs and medical conferences. These forthcoming events will provide a valuable opportunity for UTime to showcase its latest achievements in medical devices and solutions and to enhance its communication and partnerships within the global medical industry. At the upcoming MEDICA in Düsseldorf, Germany, one of the world's most influential medical trade fairs for medical technology and devices, UTime plans to exhibit its latest innovations in medical monitoring devices and smart diagnostic tools.
SHENZHEN, China, Aug. 21, 2024 /PRNewswire/ -- UTime Limited (NASDAQ:WTO) ("UTime" or the "Company") is pleased to announce its ambitious strategy for advancing AI-driven health solutions. Recognizing the growing value and potential of smart health technologies, UTime is committing significant investments to expand its smart medical wearable products business. In strategic collaboration with Dr. Ehud Baron, a renowned figure in medical technology innovation, UTime is set to enhance its offerings in blood pressure measurement and extend into hemodynamic and health mapping products. Dr. Baron will collaborate with UTime's team to develop comprehensive plans for a diverse range of health produ
SHENZHEN, China, Aug. 19, 2024 /PRNewswire/ -- UTime Limited (NASDAQ:WTO) ("UTime" or the "Company") is pleased to announce a Memorandum of Understanding ("MOU") with XCardio, a Japanese company owned by Dr. Ehud Baron, a leader in medical technology innovation. This partnership focuses on the joint development of state-of-the-art continuous blood pressure monitoring devices, BPWatch, aimed at advancing cardiovascular disease management. This joint project also aims to develop a new revenue model by transitioning from the low-margin business of selling BP watches to consumers to a high-margin, recurring revenue model. This will involve selling high-margin systems using a Per Patient Per Mont